Uveitis News and Research

RSS
Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.
Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021

Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021

Bacteria in gut may be the cause of uveitis in the eye

Bacteria in gut may be the cause of uveitis in the eye

New study suggests novel ways to treat serous retinal detachment

New study suggests novel ways to treat serous retinal detachment

OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell to present at upcoming US and French investment conferences

TxCell to present at upcoming US and French investment conferences

TxCell invited to speak at largest US meeting for investors in emerging growth companies

TxCell invited to speak at largest US meeting for investors in emerging growth companies

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Researchers find unique cell type that can protect against uveitis

Researchers find unique cell type that can protect against uveitis

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

EMA grants Advanced Therapy Medicinal Product classification for TxCell's Col-Treg

EMA grants Advanced Therapy Medicinal Product classification for TxCell's Col-Treg